Advice

following a full submission assessed under the end of life and orphan equivalent process:

avelumab (Bavencio®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.

In a phase III study, maintenance treatment with avelumab plus best supportive care (BSC) significantly improved overall survival when compared with BSC alone.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
avelumab (Bavencio)
SMC ID:
SMC2359
Indication:

As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy

Pharmaceutical company
Merck
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
09 August 2021